
EUROGIN - International Multidisiplinary HPV Congress
🎯 Selling to this event's audience? Get a free tailored buyer list
Tell us your work email and our AI instantly builds a buyer list matched to EUROGIN - International Multidisiplinary HPV Congress — the best‑fit companies to target, the exact decision‑maker job titles, and the industry filters that fit what you sell.
About this event
EUROGIN – International Multidisciplinary HPV Congress (EUROGIN)
Overview
EUROGIN is positioned as the leading international congress focused on HPV infections and associated cancers, with a clear mission to translate scientific and evidence-based research into clinical practice. The program spans research-oriented scientific sessions as well as clinically oriented sessions intended to help participants integrate knowledge into day-to-day practice.
Dates & Location
- Dates: Feb. 10–13, 2027
- Venue: Bologna Congress Center
- City/Country: Bologna, Italy
Event Type
This is a medical/scientific congress with a multidisciplinary structure combining:
- Scientific sessions covering HPV infections and related diseases, including screening and prevention
- Clinical sessions designed to help participants apply learning in everyday practice
- Free communications for sharing latest research with a global professional audience
1) Who Attends (Buyers / Attendees)
EUROGIN is not a consumer-focused event; it is a qualified healthcare and research audience congress. The “buyer” layer is best understood as the decision-makers who influence research direction, clinical guideline uptake, screening/prevention implementation, and technology adoption in HPV-related care pathways.
Primary attendee groups (high-likelihood buyer personas):
- Clinical decision-makers: gynecologists, oncologists, infectious disease specialists, screening program leaders, and other clinicians working in HPV-related prevention and early diagnosis
- Academic & research leaders: principal investigators, study directors, clinical researchers, and poster/oral presenters across HPV epidemiology, prevention, diagnostics, and patient outcomes
- Screening & public health stakeholders: professionals involved in cervical cancer screening strategies, HPV prevention programs, and early detection pathways
- Laboratory and diagnostics stakeholders: clinical lab professionals, translational research teams, and diagnostic implementation specialists (especially around screening methods and HPV testing approaches)
- Industry-facing professionals (sponsors/exhibitors): representatives from medical technology, diagnostics, and related healthcare innovation companies (typically concentrated in sponsor/exhibit roles rather than general attendees)
- Conference contributors: authors, poster presenters, and those participating via abstract formats (which often correlate with organizational research/clinical influence)
2) Where the Show Is Happening + Attendee Geographic Origin
Show location: Bologna Congress Center, Bologna, Italy (Feb. 10–13, 2027).
Expected geographic pattern:
- The congress is explicitly international, with attendees coming from 90 countries (as stated in the event’s facts & figures).
- Since the event is held in Italy, there will likely be a strong European presence, but the stated footprint indicates it is designed to attract global participation.
For outreach purposes, the most practical geographic targeting is:
- Europe-first (short travel, strong alignment with screening/public health programs)
- Global secondary layer (countries represented through the 90-country attendance)
3) Audience Reach (Local / National / Global)
EUROGIN’s audience reach is best categorized as global. The event reports:
- 90 countries represented
- 1,600+ participants
4) Sample Buyer Company Names (BUYERS ONLY) + Websites
We can provide buyer-focused company targets, but we need one more input to ensure we match your client’s exact needs and product category (see Section 8 below).
Until we receive that, below are buyer-leaning sample target types and example organizations commonly connected to HPV prevention, screening, diagnostics, and clinical technology ecosystems. Use these as starting points for research and prioritization.
| Priority | Company | Website | Best Title to Target | Why This is a Good Buyer Fit |
|---|---|---|---|---|
| 1 | Roche Diagnostics | https://www.roche.com | Global Product Manager, HPV / Molecular Diagnostics Clinical Affairs Director (Diagnostics) |
Strong alignment with clinical diagnostics and molecular testing used in screening and related clinical workflows. |
| 2 | Abbott | https://www.abbott.com | Medical Affairs Director / Diagnostics Marketing Director, Molecular/Immunoassay Testing |
Relevant to laboratory and diagnostic pathways where HPV testing and clinical adoption decisions are influenced by clinical and evidence programs. |
| 3 | Hologic | https://www.hologic.com | VP, Clinical Affairs (Women’s Health) Director, Product Management (Diagnostics) |
Direct connection to women’s health and screening-adjacent diagnostic offerings and clinical evidence generation/communication. |
| 4 | Qiagen | https://www.qiagen.com | Head of Clinical Applications (Molecular) Regional Sales Director, Molecular Diagnostics |
Relevant to molecular workflow tooling and evidence-driven adoption of HPV-related testing methodologies. |
| 5 | Thermo Fisher Scientific | https://www.thermofisher.com | Director, Clinical Research Solutions Global Marketing Manager (Diagnostics/Clinical) |
Broad instrumentation and clinical research support that can be used in HPV diagnostics and research pipelines. |
| 6 | Danaher (Diagnostics / Life Sciences) | https://www.danaher.com | Clinical Program Director Business Unit Director (Diagnostics) |
Large diagnostics ecosystem—often engages in evidence and clinical adoption discussions tied to screening and prevention programs. |
| 7 | GSK | https://www.gsk.com | Medical Director / Clinical Strategy (Vaccines) Market Access Lead (Immunization Programs) |
HPV prevention is vaccine-linked; stakeholders involved in clinical strategy and market access typically attend or sponsor major scientific congresses. |
| 8 | MSD (Merck & Co.) | https://www.msd.com | Director, Medical Affairs (Vaccines / Oncology) Global Public Health Program Lead |
HPV-related prevention and evidence communication aligns with the congress’s prevention/diagnostics focus. |
| 9 | Siemens Healthineers | https://www.siemens-healthineers.com | Clinical Affairs Manager (Diagnostics) Product Marketing Manager (Women’s Health) |
Supports diagnostic innovation and clinical implementation conversations in women’s health and screening-linked testing. |
| 10 | Genetic testing / pathology vendors (example: Guardant-type ecosystem) | https://www.yourcompanyexample.com | Head of Clinical Partnerships Director, Oncology/Prevention Clinical Programs |
HPV-associated cancer prevention/early detection increasingly intersects with advanced clinical and molecular strategies (needs validation with your product fit). |
Note: We intentionally kept the list “buyer-leaning” and aligned to the congress themes. After you share your client website and product category, we will produce a much tighter, higher-conversion buyer list (titles + priorities + matching companies).
5) Job Profiles, Industries & Event Type
High-value job profiles to target:
- Medical Directors (vaccines, women’s health, clinical strategy)
- Clinical Affairs / Medical Affairs leadership (evidence, study communication, adoption)
- Head of Clinical Programs and Clinical Research Directors
- VP/Director Product Management (HPV testing, women’s health diagnostics)
- Market Access / Public Health Program Leaders (screening & prevention ecosystem)
- Diagnostics/Pathology Laboratory Directors (implementation, validation workflows)
- Screening Program Directors (cervical cancer screening pathway roles)
- Academic/Research Principal Investigators (poster/oral presenter leadership roles)
- Business Development / Partnerships (clinical collaborations, site network expansion)
Industries most associated with this event’s buyer intent:
- Pharmaceuticals (HPV prevention and associated clinical research)
- Medical Devices (women’s health and related clinical solutions)
- Medical/Healthcare providers and research institutions (clinical and scientific adoption)
- Diagnostics / Clinical laboratories / Translational research tooling
- Hospital & Health Care (screening program leadership and clinical pathway implementers)
- Research and Program Development (evidence generation and education)
- Events Services is present through sponsorship/exhibition logistics, but buyer intent typically concentrates in clinical/science stakeholders rather than pure event vendors
Event type (what participants come for):
- International medical/scientific congress
- HPV research dissemination + prevention/diagnostics advancement
- Clinical integration sessions (practical application)
- Abstracts and posters for latest findings
6) Estimated Attendance (Expected Total Footfall)
EUROGIN reports 1,600+ participants and 660+ speakers / poster presenters, along with 725 oral presentations.
For planning outreach expectations, the best stated indicator for footfall is the 1,600+ participant figure.
7) Key Focus Areas & Buyer Engagement
Core scientific/clinical focus areas:
- HPV infections and related diseases
- Screening (including prevention-linked detection approaches)
- Prevention strategies and public health direction
- Diagnostics integration into clinical practice
- Clinical translation from research into day-to-day clinical workflows
- Free communications to share the newest research findings globally
Best buyer engagement angles (what resonates with decision-makers):
- Evidence and outcomes: emphasize clinical utility, study data, and implementation evidence
- Prevention pathway support: connect to screening and prevention program adoption
- Clinical workflow relevance: highlight how products/solutions reduce time-to-action in screening/diagnostics
- Global collaboration: align with an international network of researchers and clinicians (the event explicitly draws 90 countries)
- Educational impact: address clinical session learning and integration into practice
8) Client Product Review (We need your client website)
To determine the best buyer types and priority companies for your specific requirement, we need your client website. Please share the website URL so we can map your offering to the most relevant buyer segment and produce a prioritized list of buyer companies and job titles.
What we will do once you share the website:
- Identify whether your product is strongest in vaccines / pharma, diagnostics, medical devices, clinical workflow tools, or services
- Translate that into buyer job profiles (clinical affairs, medical directors, product management, screening program leadership, etc.)
- Select companies that are the closest match to your product category and typical buyer behavior at congresses
- Return an upgraded buyer list with Priority, Company, Website, Best Title to Target, and Why This is a Good Buyer Fit
If you paste the website here, we can proceed with the buyer prioritization immediately.
9) Recommended Industry Targeting (from your industry taxonomy)
Based on the congress topic (HPV prevention, screening, diagnostics, clinical translation), the most relevant industry categories to prioritize are:
- Pharmaceuticals
- Medical Devices
- Hospital & Health Care
- Research
- Biotechnology
- Medical Practice
- Program Development
- Education Management (only where clinical education/programming is part of the company’s offering)
- Events Services (only for sponsor/exhibit agencies—usually not the primary clinical buyer persona)
Data Points We Can Reliably Use From the Event Source
- Date: Feb. 10–13, 2027
- Venue: Bologna Congress Center
- City/Country: Bologna, Italy
- Participants: 1,600+ participants
- Countries represented: 90 countries
- Speakers / poster presenters: 660+
- Oral presentations: 725
Next Step
Please share your client website and a 1–2 sentence description of what your client sells. We will then produce a tighter buyer list aligned to the congress’s HPV prevention/screening/diagnostics ecosystem, including a 15–20 row sample table with the columns: Priority, Company, Website, Best Title to Target, Why This is a Good Buyer Fit.
Data sheet
| Event Name | EUROGIN - International Multidisciplinary HPV Congress |
|---|---|
| Event Date | 10–13 February 2027 |
| Event Status | Upcoming |
| Venue | Bologna Congress Center |
| City | Bologna |
| State / Region | Emilia-Romagna |
| Country | Italy |
| Organizer | Informa PLC / EUROGIN |
| Official Event Website | eurogin.com/en/home.html |
| Event Type | International multidisciplinary scientific congress with sponsorship and exhibition opportunities |
| Primary Category | Medical & Pharma |
| Secondary Applicable Categories | Science & Research; Wellness, Health & Fitness |
| Audience Reach | Global |
| Estimated Attendance / Expected Footfall | Attendance figure not publicly confirmed by the organizer. Official website cites 1,600+ participants for a prior edition as historical reference. |
| Attendance Data Reliability | Medium for historical evidence; low for current edition forecast |
| Main Purpose of Event | To exchange scientific and clinical evidence on HPV infections, prevention, diagnostics, screening, and associated cancers, and to translate research into clinical practice. |
EUROGIN is a leading international congress focused on HPV infections and associated cancers, with strong emphasis on prevention, diagnostics, screening, and clinical translation. The official program structure highlights scientific sessions, clinical sessions, and free communications, making it a high-value forum for researchers, clinicians, diagnostics companies, and public health stakeholders.
The event matters because it convenes a global, specialized audience around cervical cancer prevention, HPV-related oncology, and evidence-based practice. For exhibitors and sponsors, EUROGIN offers access to decision-makers and influencers involved in clinical research, screening programs, laboratory testing, medical devices, diagnostics, therapeutics, and healthcare policy.
| Buyer / Attendee Segment | Typical Organizations | Buying Role or Influence | Relevance to Exhibitors / Suppliers |
|---|---|---|---|
| Clinical researchers and principal investigators | Universities, cancer centers, research institutes, hospitals | Protocol selection, study design, product evaluation | High relevance for diagnostics, assays, biomarker platforms, and clinical research tools |
| Gynecologists and oncologists | Hospitals, specialty clinics, academic medical centers | Clinical adoption and product recommendation | Key audience for screening, treatment, prevention, and clinical workflow solutions |
| Public health and screening program leaders | Health ministries, public health agencies, screening authorities | Program selection, policy influence, procurement input | Relevant for population screening, self-sampling, and implementation partners |
| Laboratory directors and pathology leaders | Reference labs, hospital labs, diagnostic networks | Test menu approval, platform purchasing influence | Strong fit for molecular diagnostics, automation, and lab workflow vendors |
| Medical device and diagnostics buyers | Hospitals, diagnostic companies, distributors | Technology sourcing and vendor evaluation | Relevant for HPV test systems, sample collection tools, and lab automation |
| Procurement and sourcing teams | Hospitals, public health systems, research centers, universities | Purchasing, tender management, vendor shortlist creation | Important for commercial teams selling equipment, consumables, and services |
| Biopharma and vaccine stakeholders | Pharmaceutical companies, vaccine developers, biotech firms | Partnerships, research collaboration, commercial strategy | Relevant for prevention, immunization, and evidence generation ecosystems |
| Health technology assessment and policy experts | Government bodies, advisory boards, research agencies | Guideline development and reimbursement influence | Relevant for market access, evidence, and adoption strategy |
| Professional association leaders and educators | Medical associations, educational bodies, specialty societies | Agenda influence, educational partnerships | Useful for sponsorship, thought leadership, and CME-style education |
| Life science media and publishers | Medical publishers, conference media, scientific journals | Content amplification and event visibility | Supports awareness, speaker promotion, and product positioning |
| Geographic Area | Likely Attendee Origin | Buyer Concentration | Notes |
|---|---|---|---|
| Host city: Bologna | Local hospitals, universities, research centers, regional healthcare institutions | Medium | Convenient access for Italian academic and clinical attendees |
| Host region: Emilia-Romagna | Regional health systems, medical universities, public health bodies | Medium | Strong regional research and healthcare base |
| Nearby business hubs | Milan, Rome, Florence, Padua, Turin | High | Major Italian healthcare, pharma, and academic sourcing centers |
| National reach: Italy | Clinicians, researchers, hospital leaders, public health officials | High | Italy is a core host market for clinical and life-science participation |
| European reach | Hospitals, universities, screening bodies, diagnostics firms across Europe | Very High | HPV prevention and cervical screening are strongly driven by European clinical systems |
| International reach | Global scientific community, especially from diagnostics and oncology ecosystems | High | Official website cites participation from 90 countries as historical evidence |
| Reach Level | Assessment | Explanation |
|---|---|---|
| Global | Primary classification | The official website describes EUROGIN as the world’s leading international congress on HPV infections and associated cancers and reports participation from 90 countries in prior-event evidence. |
| Buyer Company / Organization | Buyer Type | Why It Is Relevant | Website | Best Job Titles to Target | Evidence Level |
|---|---|---|---|---|---|
| World Health Organization | Government / public health | Global HPV prevention and screening policy relevance | who.int | Program Officer, Technical Officer, Public Health Specialist | Strong Market Fit, Attendance Not Confirmed |
| European Centre for Disease Prevention and Control | Government / public health | Relevant to screening programs, surveillance, and prevention strategy | ecdc.europa.eu | Senior Expert, Epidemiologist, Policy Officer | Strong Market Fit, Attendance Not Confirmed |
| AstraZeneca | Pharma / biotech | Oncology and vaccine-adjacent scientific and commercial relevance | astrazeneca.com | Medical Affairs Director, Clinical Development Lead, Partnerships Director | Strong Market Fit, Attendance Not Confirmed |
| Roche | Diagnostics / pharma | Strong fit for HPV testing, molecular diagnostics, and pathology workflows | roche.com | Global Product Manager, Laboratory Solutions Leader, Business Development Director | Strong Market Fit, Attendance Not Confirmed |
| Abbott | Diagnostics / medical devices | Potential buyer and partner for molecular diagnostic platforms and screening tech | abbott.com | Director of Diagnostics, Product Marketing Manager, Clinical Affairs Director | Strong Market Fit, Attendance Not Confirmed |
| Qiagen | Life sciences / diagnostics | Directly aligned with HPV testing, sample prep, and molecular workflows | qiagen.com | Product Manager, Medical Affairs, Strategic Partnerships Manager | Strong Market Fit, Attendance Not Confirmed |
| Hologic | Diagnostics / women’s health | High relevance to cervical cancer screening and women’s health diagnostics | hologic.com | Business Development Director, Clinical Applications Manager, National Sales Director | Strong Market Fit, Attendance Not Confirmed |
| BD (Becton, Dickinson and Company) | Medical devices / diagnostics | Relevant for specimen collection, lab consumables, and diagnostics channel opportunities | bd.com | Director of Diagnostics, Procurement Manager, Product Manager | Strong Market Fit, Attendance Not Confirmed |
| Thermo Fisher Scientific | Life sciences / lab instruments | Relevant for PCR, molecular testing, and laboratory infrastructure buyers | thermofisher.com | Lab Solutions Director, Category Manager, Strategic Account Director | Strong Market Fit, Attendance Not Confirmed |
| Siemens Healthineers | Medical technology | Potential buyer for clinical diagnostics and hospital-based technology partnerships | siemens-healthineers.com | Business Unit Director, Product Manager, Medical Affairs Lead | Strong Market Fit, Attendance Not Confirmed |
| GSK | Pharma / vaccines | Relevant to HPV prevention, immunization, and public health collaboration | gsk.com | Medical Director, Public Affairs Lead, Partnership Manager | Strong Market Fit, Attendance Not Confirmed |
| Merck & Co., Inc. | Pharma / vaccines | Relevant to vaccination strategy, oncology, and scientific exchange | merck.com | Medical Affairs Director, Commercial Strategy Lead, Scientific Affairs Manager | Strong Market Fit, Attendance Not Confirmed |
| Hospital Clínic de Barcelona | Hospital / academic medical center | Likely scientific attendee organization for screening and oncology work | clinicbarcelona.org | Department Head, Clinical Research Director, Procurement Manager | Strong Market Fit, Attendance Not Confirmed |
| Institut national du cancer (INCa) | Government / cancer agency | Relevant to screening policy, prevention, and oncology program planning | e-cancer.fr | Program Director, Policy Officer, Public Health Lead | Strong Market Fit, Attendance Not Confirmed |
| Priority | Job Title / Function | Department | Seniority Level | Why This Role Matters |
|---|---|---|---|---|
| 1 | Medical Affairs Director | Medical Affairs | Director | Owns scientific engagement, evidence generation, and clinical credibility |
| 2 | Clinical Development Lead | Clinical Development | Senior Manager / Director | Influences study design, trial strategy, and research partnerships |
| 3 | Laboratory Director | Clinical Laboratory / Pathology | Director | Decision-maker for diagnostics, instrumentation, and workflow solutions |
| 4 | Procurement Manager | Procurement / Supply Chain | Manager | Evaluates vendors, pricing, and tender compliance for labs and hospitals |
| 5 | Public Health Program Lead | Public Health / Screening Programs | Lead / Director | Shapes screening adoption, prevention strategy, and implementation partnerships |
| 6 | Director of Diagnostics | Diagnostics | Director | Owns product portfolio and adoption for molecular testing solutions |
| 7 | Strategic Partnerships Director | Partnerships / Business Development | Director | Targets collaborations between vendors, clinics, research bodies, and public health systems |
| 8 | Category Manager | Commercial / Procurement | Manager | Important for sourcing consumables, diagnostics, and service contracts |
| Priority | Apollo Industry | Why It Fits the Event | Best Buyer Use Case |
|---|---|---|---|
| 1 | Hospital & Health Care | Primary end-user environment for screening, oncology, and clinical adoption | Hospital leaders, department heads, clinical buyers |
| 2 | Pharmaceuticals | Relevant to HPV prevention, oncology, and medical education | Medical affairs, clinical development, partnerships |
| 3 | Biotechnology | Strong fit for diagnostics, biomarkers, and translational research | Research, product, scientific affairs |
| 4 | Medical Devices | Relevant for specimen collection, screening equipment, and clinical devices | Product managers, sales leaders, clinical teams |
| 5 | Medical Practice | Direct connection to clinicians, specialists, and diagnostics adopters | Physicians, practice administrators, clinical leaders |
| 6 | Government Administration | Important for screening program funding, reimbursement, and public health policy | Policy makers, public health officers, procurement teams |
| 7 | Research | Core audience for the congress’s scientific exchange model | Investigators, research managers, translational teams |
| 8 | Higher Education | Universities contribute faculty, abstracts, and clinical research attendees | Professors, research directors, department chairs |
| 9 | Information Technology & Services | Relevant for data management, digital screening, and research platforms | IT directors, digital health, data platform teams |
| Metric | Figure | Status | Source / Basis | Notes |
|---|---|---|---|---|
| Estimated total footfall | 1,500–1,800 | Estimated | Based on official prior-edition figure of 1,600+ participants | Current edition not publicly confirmed |
| Exhibitor count | Not publicly confirmed | Confirmed unavailable | Official 2027 public site content reviewed | Exhibitor/sponsor pages exist, but count not visible in provided content |
| Buyer count | Not publicly confirmed | Confirmed unavailable | No official buyer list published in provided source | Use attendee profiling rather than named buyer count |
| Speaker count | 660+ speakers / poster presenters | Historical / prior-year evidence | Official website facts & figures | Useful indicator of scientific depth |
| Sponsor count | Not publicly confirmed | Confirmed unavailable | Sponsor/exhibitor pages listed, count not provided in available content | Check sponsor brochure for commercial prospecting |
| Historical attendance | 1,600+ participants; 90 countries | Historical / prior-year evidence | Official website facts & figures | Best available public benchmark for current planning |
| Focus Area | Typical Buyer Need | Buyer Engagement Opportunity | Relevant Supplier Offering |
|---|---|---|---|
| Screening | Improved detection rates and patient access | Clinical evidence discussions, implementation case studies, workflow demos | Screening platforms, self-sampling, logistics support |
| Diagnostics | Accurate, scalable HPV testing and lab automation | Product comparisons, lab workflow optimization, validation data | Molecular assays, instruments, consumables |
| Prevention and vaccination | Evidence on vaccine strategy and public health impact | Thought leadership, public health collaboration, medical education | Vaccines, educational programs, epidemiology support |
| Clinical oncology | New evidence on HPV-related cancers and care pathways | Symposia, expert meetings, investigator outreach | Oncology therapies, diagnostics, service lines |
| Translational research | Bridge from lab findings to clinical practice | Abstract engagement, investigator sponsorships, collaborations | Research services, biomarker tools, data platforms |
| Public health policy | Guidelines, reimbursement, implementation models | Roundtables with agencies and screening leaders | Policy support, evidence packages, advocacy resources |
| Factor | Assessment | Explanation |
|---|---|---|
| Buyer relevance | Very High | The congress attracts clinicians, researchers, public health leaders, lab directors, diagnostics stakeholders, and healthcare decision-makers. |
| Decision-maker availability | High | The audience includes directors, senior scientists, heads of departments, and program leaders. |
| Data collection potential | Medium | Scientific congresses often provide speaker and sponsor data, but current-year attendee lists are not publicly confirmed in the provided content. |
| Apollo targeting potential | Very High | Clear fit for healthcare, pharma, diagnostics, public health, research, and academic institutions. |
| Geographic targeting potential | High | Strong targeting opportunities across Italy, Europe, and global HPV-related research markets. |
| Best outreach approach | Very High | Target scientific sponsorship, diagnostics partnerships, abstract-related outreach, and senior-level direct mail/email campaigns. |
| Overall lead quality | High | Excellent for life sciences, diagnostics, screening, and healthcare market development. |
| Best use case | B2B attendee list building and sponsored outreach | Strong for lead generation agencies, event-data products, diagnostics vendors, and pharma marketing teams. |
| Limitations / risks | Moderate | Current-year attendee and exhibitor names are not confirmed in the provided source content, so attendee-level precision is limited. |
| Filter Type | Recommended Filters | Purpose |
|---|---|---|
| Apollo industries | Hospital & Health Care; Pharmaceuticals; Biotechnology; Medical Devices; Research; Government Administration; Higher Education; Information Technology & Services; Medical Practice; Public Policy | Match the congress’s clinical, scientific, and public health audience |
| Departments | Medical Affairs; Clinical Development; R&D; Diagnostics; Procurement; Supply Chain; Public Health; Pathology/Laboratory; Partnerships; Business Development | Prioritize roles that evaluate, influence, or purchase relevant solutions |
| Seniority | Manager; Director; VP; CXO; Head; Senior Scientist; Lead | Focus on decision-makers and technical influencers |
| Job titles | Medical Affairs Director, Laboratory Director, Clinical Development Lead, Procurement Manager, Public Health Program Lead, Director of Diagnostics, Strategic Partnerships Director, Category Manager, Chief Medical Officer, Head of Screening Programs | Best-fit roles for direct outreach and attendee-list enrichment |
| Geography | Italy; Europe; United Kingdom; Germany; France; Spain; Benelux; Nordics; North America | Reflects the global participant base and likely travel patterns |
| Employee size | 51–200; 201–500; 501–1,000; 1,001–5,000; 5,001+ | Captures hospitals, universities, diagnostics firms, and global life science companies |
| Keywords | HPV, cervical screening, oncology, diagnostics, molecular testing, pathology, prevention, self-sampling, public health, biomarker, screening program | Narrow search to event-relevant organizations and contacts |
| Company type | Private, Public, Government, Hospital, University, Research Institute | Capture the mixed scientific and institutional audience |
| Source | Type | What It Verified | Reliability |
|---|---|---|---|
| EUROGIN official website | Official organizer website | Event name, dates, venue, city, country, audience focus, program structure, sponsor/exhibit section, and historical facts & figures | High |
| EUROGIN Facts & Figures section | Official event statistics | 1,600+ participants, 90 countries, 660+ speakers/poster presenters, 725 oral presentations | High for historical reference |
| EUROGIN sponsor/exhibit and program pages | Official navigation content | Confirmed existence of sponsorship, exhibition, abstracts, posters, and agenda components | High |
| Ethical MedTech reference on official site | Official compliance notice | EthicalMedTech compliance reference for a prior congress edition | High |
🎯 Selling to this event's audience? Get a free tailored buyer list
Tell us your work email and our AI instantly builds a buyer list matched to EUROGIN - International Multidisiplinary HPV Congress — the best‑fit companies to target, the exact decision‑maker job titles, and the industry filters that fit what you sell.